Tabarkiewicz Jacek, Rybojad Pawel, Jablonka Andrzej, Rolinski Jacek
Department of Clinical Immunology, Skubiszewski Medical University, 20-095 Lublin, Poland.
Oncol Rep. 2008 Jan;19(1):237-43.
Dendritic cells (DCs) are the most potent antigen presenting cells, which can stimulate a cellular immune response against malignant tumor cells. Many authors have described the phenomenon of tumor infiltration by dendritic cells and emphasized an immunosuppressive tumor influence on DC function. In the present study, we examined the presence of myeloid CD1c+ (BDCA-1+) dendritic cells and lymphoid/plasmacytoid CD303+ (BDCA-2+) dendritic cells in peripheral blood, lymph nodes and cancer tissue of patients with non-small cell lung cancer (NSCLC). Fifty male patients treated surgically for NSCLC stages I-IIIa without neoadjuvant chemotherapy were included. Employing a multiparameter flow cytometry for CD1c, CD19, CD123 and CD303, we observed an accumulation of immature DCs in the tissues involved in the neoplasmatic process with the predominance of lymphoid/plasmacytoid over myeloid DCs. Moreover, in peripheral blood NSCLC patients had a significantly lower percentage of CD1c+ DCs than healthy donors. Our results suggest that NSCLC cells might hamper the maturation of DCs, thus escaping an efficient immune response.
树突状细胞（DCs）是最有效的抗原呈递细胞，能够刺激针对恶性肿瘤细胞的细胞免疫反应。许多作者描述了树突状细胞浸润肿瘤的现象，并强调肿瘤对DC功能具有免疫抑制作用。在本研究中，我们检测了非小细胞肺癌（NSCLC）患者外周血、淋巴结和癌组织中髓样CD1c+（BDCA-1+）树突状细胞和淋巴样/浆细胞样CD303+（BDCA-2+）树突状细胞的存在情况。纳入了50例接受手术治疗的I-IIIa期NSCLC男性患者，未进行新辅助化疗。采用针对CD1c、CD19、CD123和CD303的多参数流式细胞术，我们观察到在肿瘤形成过程涉及的组织中未成熟DCs聚集，其中淋巴样/浆细胞样DCs多于髓样DCs。此外，NSCLC患者外周血中CD1c+ DCs的百分比显著低于健康供者。我们的结果表明，NSCLC细胞可能会阻碍DCs的成熟，从而逃避有效的免疫反应。
